Award
Fox Chase Cancer Center 11330520
Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer
Recipient
Research Institute of Fox Chase Cancer Center
Award Amount
$470,000.00
Ceiling
$470,000.00
Awarded
July 23, 2026
Identifier
11330520
Award for validating blood-based predictive biomarkers to assess therapeutic response in rectal cancer patients, funded by the National Cancer Institute with $470,000.
Description
This project involves the validation of blood-based biomarkers for predicting therapeutic response in rectal cancer patients, funded by the National Cancer Institute, with a total award amount of $470,000. The project spans from May 2026 to April 2027, with a focus on assay development, validation, and clinical utility assessment.